This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nevro Corp. Announces Publication Of Positive Six-Month Clinical Data For Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy In Europe

MENLO PARK, Calif., Feb. 6, 2013 /PRNewswire/ -- Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, today announced publication of six-month safety and efficacy data from a European study evaluating the company's Senza ® High-Frequency Spinal Cord Stimulation (HF-SCS) system.  The Senza system is presently authorized for sale in Europe and Australia.

The findings were published in Neuromodulation: Technology at the Neural Interface, a peer-reviewed publication of the International Neuromodulation Society.  The 83-patient study evaluated patients with predominant back or leg pain, including a subset of patients who previously failed traditional low-frequency SCS treatment.  In this challenging cohort, the data demonstrated that the Senza system provided significant and sustained relief for low back pain and leg pain in more than 70 percent of treated patients, and did so without triggering the tingling sensation—known as paresthesia—that is typically associated with traditional low-frequency SCS systems.  Patients using the Senza system also experienced significant reductions in pain medication use, significant improvement in their disability, and significant improvement in their ability to sleep.

"The results of this study provide further evidence of the favorable safety and efficacy profile of Nevro's High-Frequency SCS system," said Dr. Jean-Pierre Van Buyten, Director of the Multidisciplinary Pain Centre at AZ Nikolaas in Belgium and lead author of the study.  "Patients with intractable back and leg pain are usually desperate for relief and for a solution that will allow them to resume a normal life.  I have seen firsthand with my own patients the vast improvements in quality of life that Nevro's system has provided."

The prospective, open-label, multicenter European trial enrolled 83 patients with significant back pain.  After a trial period, 88 percent (72 of 82) of patients reported a significant improvement in Visual Analog Scale (VAS) pain scores and underwent permanent implantation of the Senza system.  For patients receiving permanent implants, mean back pain VAS of 8.4 before treatment was reduced 68 percent, to 2.7 at six months (p<0.001).  Mean leg pain VAS of 5.4 before treatment was reduced 74 percent, to 1.4 at six months (p<0.001).  Of the 72 patients still participating in the European trial at six months, 74 percent (53 of 72) had greater than 50 percent back pain relief six months after implantation.  

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs